Physician profile
Sameer Khan
NPI 1205364759
$28,506.23
in general payments reported to CMS, 2019-2025
13 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $71.40 · 2023: $418 · 2024: $101 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,891.25 |
| Food and Beverage | $2,423.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $24,604.29 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $2,868.55 | 2025 | Iqirvo |
| Abbvie INC. | $273.24 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $226.31 | 2021-2025 | Eohilia, Entyvio, Livtencity |
| Gilead Sciences, INC. | $160.79 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $119.92 | 2023 | Zeposia |
| Pfizer INC. | $60.93 | 2025 | |
| Intercept Pharmaceuticals, INC. | $52.22 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.90 | 2022-2023 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $39.17 | 2024 | Terlivaz |
| Ardelyx, INC. | $19.16 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.28 | 2025 | Dupixent |
| Boston Scientific Corporation | $14.47 | 2023 | Agile Esophageal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.